Trial Profile
An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 24 Apr 2024
Price :
$35
*
At a glance
- Drugs Acalabrutinib (Primary) ; Lenalidomide; Rituximab
- Indications Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Acerta Pharma
- 13 Nov 2023 Planned End Date changed from 25 Aug 2023 to 29 Dec 2028.
- 13 Dec 2022 Results (n=67 from R/R relapse and refractory and TN treatment naive Follicular lymphoma cohorts) assessing efficacy and safety of Acalabrutinib Plus Rituximab with or without Lenalidomide in Patients with Follicular Lymphoma presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 01 Oct 2022 Results (n=43) assessing efficacy and safety of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma, published in the British Journal of Haematology.